Incannex Healthcare Reports Increased Cash Reserves but Continued Operational Losses in Q2 FY2026

Incannex Healthcare Inc. reported its financial results for the second quarter of fiscal year 2026, revealing a significant increase in cash reserves but continued operational losses. The company ended the quarter on December 31, 2025, with cash and cash equivalents of $68.9 million, a substantial rise from $15.0 million at the end of the previous fiscal year. However, the company did not generate any revenue during the quarter, compared to $12,000 in the same period last year, reflecting a 100% decrease. For the six months ending December 31, 2025, Incannex reported a net loss of $12.9 million, up from a loss of $11.3 million in the prior year.

Operating expenses for the quarter increased by 39% to $7.0 million, compared to $5.0 million in the same quarter of 2024. This rise was primarily driven by a 61% increase in research and development (R&D) expenses, which totaled $2.3 million, attributed to costs associated with the IHL-42X clinical trial. General and administrative expenses also rose by 31% to $4.7 million, largely due to increased stock-based compensation and consulting fees. For the six-month period, total operating expenses reached $13.8 million, a 22% increase from $11.3 million in the previous year.

Strategically, Incannex has focused on advancing its clinical programs, including IHL-42X for obstructive sleep apnea and IHL-675A for rheumatoid arthritis. The company has paused patient recruitment for IHL-675A to reallocate resources towards IHL-42X, which is currently in late-stage clinical trials. Additionally, Incannex has expanded its operations, including a joint venture with Mind Medicine Australia to operate a psychedelic-assisted therapy clinic in Melbourne, which has contributed to a slight increase in the share of earnings from joint ventures.

The company’s operational metrics indicate a strong focus on R&D, with plans to continue increasing expenditures as clinical trials progress. As of December 31, 2025, Incannex's current assets exceeded current liabilities by $72.0 million, a significant improvement from $13.0 million at the end of June 2025. This financial cushion is expected to support the company’s operations for at least the next twelve months. Looking ahead, Incannex anticipates that its cash reserves, along with potential future financing, will be sufficient to fund ongoing development activities, although it acknowledges the inherent uncertainties in drug development and the need for additional capital in the future.